JAMA/tukuz.com
Feb 7, 2026, 06:50
ACOG 2023 Guideline on Premenstrual Disorders – JAMA
JAMA shared a post on LinkedIn:
“JAMA Clinical Guidelines Synopsis: The 2023 American College of Obstetricians and Gynecologists guideline on the management of premenstrual disorders recommends selective serotonin reuptake inhibitors (SSRIs)—used intermittently or continuously—as effective for affective symptoms, with evidence supporting their use.
Combined oral contraceptive pills, particularly those containing drospirenone, and cognitive behavior therapy are also recommended.
Treatment selection should consider individual patient goals, presence of affective or physical symptoms, and need for contraception.”

Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Sep 13, 2026, 15:11Sachintha Alwis: From Impaired Sperm Motility to Microrobotics
-
Sep 13, 2026, 15:08Laurence Orbuch: Before Endometriosis Surgery, Ask…
-
Sep 13, 2026, 15:05Ademola Ayodele: IUI, IVF or Egg Freezing – Which One Is Right for You?
-
Sep 13, 2026, 14:59Fiona Pathiraja-Møller: Tennis Players No Longer Have to Choose Between Career and Family
-
Sep 13, 2026, 14:571-Day Virtual Experience for People Impacted by PMOS – PCOS Awareness Association
-
Sep 13, 2026, 14:53Ozor Victor: Behind Every Embryo Is a Story of Science, Precision, and Hope
-
Sep 13, 2026, 14:50Diana Kayal: What They Don’t Tell You About IVF
-
Sep 13, 2026, 14:44Vikram Sinai Talaulikar: A Heartfelt Thank You to All Who Donated and Supported “Menopause and Cancer”
-
Sep 13, 2026, 14:41Nicole McPherson: Changing IVF Practices Is Hard – Integration Needs to Be Easy
